| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
1 Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland; 2 Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas; 3 Department of Diagnostic Science and Pathology, Dental School, University of Maryland, Baltimore, Maryland; and 4 Developmental Therapeutics Program, National Cancer Institute, NIH, Rockville, Maryland
ABSTRACT
Squamous carcinomas of the head and neck (HNSCC) represent the sixth most common cancer among men worldwide and a major cause of morbidity and mortality due to its relatively poor prognosis. As part of ongoing studies addressing the molecular events underlying tumor progression in HNSCC, we have explored the nature of the proliferative pathways in which dysregulation may promote aberrant cell growth in this tumor type. The serine/threonine protein kinase Akt is a downstream target of phosphatidylinositol 3-kinase and a key regulator of normal and cancerous growth and cell fate decisions. Therefore, in this study, we have examined the status of activation of Akt in different stages of squamous cell carcinoma development in mice and in clinical samples from HNSCC patients. By immunohistochemical analysis, using a recently developed phosphorylation state-specific antibody, we demonstrated that Akt activation correlates closely with the progression of mouse skin squamous cell carcinoma. We also observed that activation of Akt is a frequent event in human HNSCC because active Akt can be detected in these tumors with a pattern of expression and localization correlating with the progression of the lesions. In line with these observations, Akt was constitutively activated in a large fraction of HNSCC-derived cell lines. We also provide evidence that the Akt signaling pathway may represent a biologically relevant target for a novel antineoplastic agent, UCN-01, which recently has been shown to be active in cellular and xenograft models for HNSCC at concentrations safely achievable in clinically relevant situations.
This article has been cited by other articles:
|
|
 |
|
  T. L. Johnson, M. B. Lai, J. C. K. Lai, and A. Bhushan Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A Evid. Based Complement. Altern. Med., February 29, 2008; (2008) nen011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amornphimoltham, V. Patel, K. Leelahavanichkul, R. T. Abraham, and J. S. Gutkind A Retroinhibition Approach Reveals a Tumor Cell-Autonomous Response to Rapamycin in Head and Neck Cancer Cancer Res., February 15, 2008; 68(4): 1144 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Molinolo, S. M. Hewitt, P. Amornphimoltham, S. Keelawat, S. Rangdaeng, A. Meneses Garcia, A. R. Raimondi, R. Jufe, M. Itoiz, Y. Gao, et al. Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative Clin. Cancer Res., September 1, 2007; 13(17): 4964 - 4973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Crowell, V. E. Steele, and J. R. Fay Targeting the AKT protein kinase for cancer chemoprevention Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Patel, H. M. Rosenfeldt, R. Lyons, J.-M. Servitja, X. R. Bustelo, M. Siroff, and J.S. Gutkind Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion Carcinogenesis, June 1, 2007; 28(6): 1145 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation Blood, May 15, 2007; 109(10): 4415 - 4423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yu, P. M. Weinberger, C. Sasaki, B. L. Egleston, W. F. Speier IV, B. Haffty, D. Kowalski, R. Camp, D. Rimm, E. Vairaktaris, et al. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 553 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Stanford, J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells J. Virol., February 1, 2007; 81(3): 1251 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Basile, R. M. Castilho, V. P. Williams, and J. S. Gutkind Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis PNAS, June 13, 2006; 103(24): 9017 - 9022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood, March 15, 2006; 107(6): 2517 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Yang, W.-C. Chiang, T.-Y. Chou, S.-Y. Chang, P.-M. Chen, S.-C. Teng, and K.-J. Wu Increased NBS1 Expression Is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation Clin. Cancer Res., January 15, 2006; 12(2): 507 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Amornphimoltham, V. Patel, A. Sodhi, N. G. Nikitakis, J. J. Sauk, E. A. Sausville, A. A. Molinolo, and J. S. Gutkind Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck Cancer Res., November 1, 2005; 65(21): 9953 - 9961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. List, R. Szabo, A. Molinolo, V. Sriuranpong, V. Redeye, T. Murdock, B. Burke, B. S. Nielsen, J. S. Gutkind, and T. H. Bugge Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation Genes & Dev., August 15, 2005; 19(16): 1934 - 1950. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
